vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and JFrog Ltd (FROG). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $145.3M, roughly 1.2× JFrog Ltd). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 25.2%). Over the past eight quarters, JFrog Ltd's revenue compounded faster (20.4% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
ESPR vs FROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $145.3M |
| Net Profit | — | $-15.2M |
| Gross Margin | — | 77.9% |
| Operating Margin | 50.6% | -14.7% |
| Net Margin | — | -10.5% |
| Revenue YoY | 143.7% | 25.2% |
| Net Profit YoY | — | 34.4% |
| EPS (diluted) | $0.32 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $145.3M | ||
| Q3 25 | $87.3M | $136.9M | ||
| Q2 25 | $82.4M | $127.2M | ||
| Q1 25 | $65.0M | $122.4M | ||
| Q4 24 | $69.1M | $116.1M | ||
| Q3 24 | $51.6M | $109.1M | ||
| Q2 24 | $73.8M | $103.0M | ||
| Q1 24 | $137.7M | $100.3M |
| Q4 25 | — | $-15.2M | ||
| Q3 25 | $-31.3M | $-16.4M | ||
| Q2 25 | $-12.7M | $-21.7M | ||
| Q1 25 | $-40.5M | $-18.5M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-29.5M | $-22.9M | ||
| Q2 24 | $-61.9M | $-14.3M | ||
| Q1 24 | $61.0M | $-8.8M |
| Q4 25 | — | 77.9% | ||
| Q3 25 | — | 77.4% | ||
| Q2 25 | — | 76.3% | ||
| Q1 25 | — | 75.3% | ||
| Q4 24 | — | 75.4% | ||
| Q3 24 | — | 75.0% | ||
| Q2 24 | — | 78.8% | ||
| Q1 24 | — | 79.5% |
| Q4 25 | 50.6% | -14.7% | ||
| Q3 25 | -11.4% | -15.8% | ||
| Q2 25 | 8.6% | -20.4% | ||
| Q1 25 | -34.0% | -18.8% | ||
| Q4 24 | -6.4% | -21.9% | ||
| Q3 24 | -31.0% | -27.4% | ||
| Q2 24 | 3.5% | -18.6% | ||
| Q1 24 | 52.5% | -16.6% |
| Q4 25 | — | -10.5% | ||
| Q3 25 | -35.9% | -12.0% | ||
| Q2 25 | -15.4% | -17.0% | ||
| Q1 25 | -62.2% | -15.1% | ||
| Q4 24 | — | -20.0% | ||
| Q3 24 | -57.2% | -21.0% | ||
| Q2 24 | -83.9% | -13.9% | ||
| Q1 24 | 44.3% | -8.8% |
| Q4 25 | $0.32 | $-0.13 | ||
| Q3 25 | $-0.16 | $-0.14 | ||
| Q2 25 | $-0.06 | $-0.19 | ||
| Q1 25 | $-0.21 | $-0.16 | ||
| Q4 24 | $-0.14 | $-0.21 | ||
| Q3 24 | $-0.15 | $-0.21 | ||
| Q2 24 | $-0.33 | $-0.13 | ||
| Q1 24 | $0.34 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $704.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $887.4M |
| Total Assets | $465.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $704.4M | ||
| Q3 25 | $92.4M | $651.1M | ||
| Q2 25 | $86.1M | $611.7M | ||
| Q1 25 | $114.6M | $563.5M | ||
| Q4 24 | $144.8M | $522.0M | ||
| Q3 24 | $144.7M | $467.8M | ||
| Q2 24 | $189.3M | $591.3M | ||
| Q1 24 | $226.6M | $579.6M |
| Q4 25 | $-302.0M | $887.4M | ||
| Q3 25 | $-451.4M | $859.4M | ||
| Q2 25 | $-433.5M | $826.5M | ||
| Q1 25 | $-426.2M | $800.0M | ||
| Q4 24 | $-388.7M | $773.5M | ||
| Q3 24 | $-370.2M | $756.2M | ||
| Q2 24 | $-344.2M | $721.4M | ||
| Q1 24 | $-294.3M | $707.8M |
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.2B | ||
| Q1 25 | $324.0M | $1.2B | ||
| Q4 24 | $343.8M | $1.1B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.0B | ||
| Q1 24 | $373.1M | $997.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $50.7M |
| Free Cash FlowOCF − Capex | — | $49.9M |
| FCF MarginFCF / Revenue | — | 34.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $142.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $50.7M | ||
| Q3 25 | $-4.3M | $30.2M | ||
| Q2 25 | $-31.4M | $36.1M | ||
| Q1 25 | $-22.6M | $28.8M | ||
| Q4 24 | $-35.0M | $49.1M | ||
| Q3 24 | $-35.3M | $27.6M | ||
| Q2 24 | $-7.2M | $16.7M | ||
| Q1 24 | $53.8M | $17.5M |
| Q4 25 | — | $49.9M | ||
| Q3 25 | — | $28.8M | ||
| Q2 25 | — | $35.5M | ||
| Q1 25 | — | $28.1M | ||
| Q4 24 | — | $48.5M | ||
| Q3 24 | $-35.5M | $26.7M | ||
| Q2 24 | $-7.3M | $16.0M | ||
| Q1 24 | $53.8M | $16.6M |
| Q4 25 | — | 34.3% | ||
| Q3 25 | — | 21.0% | ||
| Q2 25 | — | 27.9% | ||
| Q1 25 | — | 23.0% | ||
| Q4 24 | — | 41.8% | ||
| Q3 24 | -68.7% | 24.5% | ||
| Q2 24 | -9.9% | 15.5% | ||
| Q1 24 | 39.0% | 16.6% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FROG
Segment breakdown not available.
